Theravance Biopharma Inc (NASDAQ:TBPH) has been given a $55.00 price objective by equities research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Wednesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 51.22% from the company’s current price.

Other research analysts have also recently issued reports about the company. ValuEngine raised Theravance Biopharma from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. BidaskClub raised Theravance Biopharma from a “hold” rating to a “buy” rating in a report on Saturday, June 24th. Leerink Swann set a $47.00 price target on Theravance Biopharma and gave the company a “buy” rating in a report on Wednesday, May 10th. Needham & Company LLC lifted their price target on Theravance Biopharma from $40.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, May 11th. Finally, Piper Jaffray Companies reissued an “overweight” rating and set a $42.00 price objective on shares of Theravance Biopharma in a report on Wednesday, March 22nd. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $41.13.

Theravance Biopharma (NASDAQ TBPH) traded down 3.73% during mid-day trading on Wednesday, hitting $36.37. 224,672 shares of the company were exchanged. The stock’s 50 day moving average is $39.20 and its 200-day moving average is $35.62. The company’s market cap is $1.94 billion. Theravance Biopharma has a 12-month low of $22.13 and a 12-month high of $43.44.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.14) by $0.13. Theravance Biopharma had a negative net margin of 2,115.94% and a negative return on equity of 81.34%. The business had revenue of $3.09 million during the quarter, compared to the consensus estimate of $5.07 million. Equities research analysts predict that Theravance Biopharma will post ($4.61) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This report was posted by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/07/23/theravance-biopharma-inc-nasdaqtbph-pt-set-at-55-00-by-cantor-fitzgerald.html.

A number of hedge funds have recently made changes to their positions in the company. Ameritas Investment Partners Inc. boosted its stake in shares of Theravance Biopharma by 1,494.3% in the first quarter. Ameritas Investment Partners Inc. now owns 3,635 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 3,407 shares in the last quarter. Aperio Group LLC purchased a new stake in shares of Theravance Biopharma during the second quarter valued at $205,000. Harvest Management LLC purchased a new stake in shares of Theravance Biopharma during the first quarter valued at $228,000. OMERS ADMINISTRATION Corp boosted its stake in shares of Theravance Biopharma by 31.9% in the first quarter. OMERS ADMINISTRATION Corp now owns 9,500 shares of the biopharmaceutical company’s stock valued at $350,000 after buying an additional 2,300 shares in the last quarter. Finally, Principal Financial Group Inc. purchased a new stake in shares of Theravance Biopharma during the first quarter valued at $420,000. 84.30% of the stock is owned by hedge funds and other institutional investors.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Analyst Recommendations for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.